Endothelial markers in malignant vascular tumours of the liver: Superiority of QB-END/10 over Von Willebrand factor and Ulex europaeus agglutinin 1

P P Anthony, P Ramani

Abstract
A new monoclonal antibody, QB-END/10, raised against the CD34 antigen in human endothelial cell membranes and haemopoietic progenitor cells, was studied for its usefulness as a marker of neoplastic vascular cells in 21 angiosarcomas and seven malignant haeman-gioendotheliomas of the liver. QB-END/10 was both more sensitive and more specific than Von Willebrand factor (VWF) and Ulex europaeus 1 agglutinin (UEA-1) in labelling endothelial cells and it did not cross react with epithelia as UEA-1 often does. Staining was uniformly strong and clear in all histological variants of these two tumours. QB-END/10 should prove particularly useful in the differential diagnosis of malignant vascular tumours of the liver.

Blood vessels are not formed solely of one type of cell or tissue constituent. Their walls are made up of endothelial cells, smooth muscle, pericytes and collagen fibres of several types, mainly those found in basement membranes. Vessels are intimately bound to tissues with which they share many of these components. The intricacy of vascular structures and their interdependence with other body constituents are complicated even further when tumours arise.

Endothelial cells, however, are an invariable component of vessels and, indeed, are unique to them. The first major advances in their identification occurred when characteristic ultrastructural features—namely, micropinocytic vesicles, Weibel-Palade bodies, and investment by a basal lamina—were recognised. This led to the reclassification of poorly understood tumours such as intravascular broncho-alveolar tumour of the lung and "histiocytoid" or "epithelioid" tumours of skin and liver as being of vascular origin. Electron microscopy, however, requires freshly collected and specially prepared tissue whereas immunocytochemistry is applicable to routine material. Antisera have therefore been raised against several antigens recently, with claims for their usefulness as endothelial markers. These include Von Willebrand factor (VWF), formerly designated as factor VIII related antigen, and blood group isoan-
tgens, but there are problems with both. Ulex europaeus agglutinin 1 (UEA-1) binds specifically to glycoproteins and glycolipids in endothelial cells, but these are also found in red blood cells and epithelia of ABH blood group secretors. Several monoclonal antibodies against endothelial cell specific antigens have been reported but so far only two, thrombomodulin and BMA 120, have been found to work in formalin fixed, paraffin wax embedded tissues, and the search for others continues.

A family of seven monoclonal antibodies against CD34 was assessed recently by a group of workers. This is a 110 kilodalton glycoprotein present in haemopoietic progenitor cells and endothelial cells where it may function as an adhesion molecule. Immunoelectron microscopical examination of umbilical artery and breast and kidney capillary vessels has shown that CD34 is concentrated on membrane processes which interdigitate between endothelial cells. CD34 messenger RNA has also been shown in extracts of umbilical vein endothelial cells, in tissue culture of the same, and in vessels of the breast, kidney, and placenta. CD34 has been purified, cloned, and sequenced and it shows no homology with any known protein including VWF, nor with UEA-1. QB-END/10 (previously named 188-27) is one of these anti-CD34 antibodies. It is an IgG molecule and binds to endothelial cells of both lymphatic and vascular origin, retaining this property after formalin fixation and paraffin wax embedding. QB-END/10 has been released for research purposes by Quantum Biosystems, Cambridge, England, and we are grateful to Dr N Bradley for a supply to evaluate its usefulness in malignant vascular tumours of the liver by comparison with VWF and UEA-1: the results from the basis of this report.

Methods
Slides from 28 liver tumours, which had been fixed in formalin and embedded in paraffin wax, were obtained from 21 cases of angiosarcoma and seven cases of malignant epithelioid haemangioendothelioma (MEH). Sixteen of the 21 cases of angiosarcoma formed part of a continuing survey conducted by the Angiosarcoma Register of the Employment Medical
Advisory Service of the Health and Safety Executive (courtesy of Dr K Campion). Six were associated with previous exposure to thorium dioxide (Thorotrust) and two to vinyl chloride monomer. All diagnoses had been agreed by a panel of pathologists (PP Anthony, RNM MacSween, and PJ Scheuer). Five were referred for consultation and were diagnosed by the same criteria. Of seven cases of MEH, one came from the Angiosarcoma Register, two from personal experience, and four had been referred for consultation. All seven had been previously investigated and diagnosed by published criteria, four by more than one expert liver pathologist.

Archival material, stained by haematoxylin and eosin, Gordon & Sweet's reticulin, periodic acid Schiff reagent and, in some cases, by VWF or UEA-1, was re-examined.

A polyclonal rabbit antibody to VWF (Dakopatts) was used at a 1 in 400 dilution. UEA-1 (Dakopatts) was used at a dilution of 1 in 400 and rabbit anti-UEA-1 (Dakopatts) at a dilution of 1 in 300. Biotinylated swine anti-rabbit antibody (Dakopatts) was used as a bridging layer for the above primary antibodies. Monoclonal mouse antibody QB-END/10 (Quantum Biosystems) was used at a dilution of 1 in 300. Biotinylated rabbit anti-mouse antibody (Dakopatts) was used as a second layer at a dilution of 1 in 200. Peroxidase conjugated avidin (Dakopatts) was used at a dilution of 1 in 500.

Paraffin wax sections were cut at 3–4 μm and stained by a modification of the avidin-biotin complex method described by Guesdon et al.17 Briefly, sections were waxed and taken to industrial methylated spirit. Endogenous peroxidase was blocked with H₂O₂ in methanol. Sections to be stained for UEA-1 in VWF were treated with trypsin (Sigma) for 10 minutes, followed by 30 minutes' incubation with normal swine serum. Sections were washed in running tap water and placed in TRIS-buffered saline (TBS) at pH 7.6. Sections were incubated with successive antibodies between washes with TBS, followed by development of the reaction product with diaminobenzidine for five to 10 minutes, counterstained with Mayer's haematoxylin, and mounted. Negative controls without antibody were run in parallel. Staining of endothelium in non-neoplastic vessels served as an endogenous positive control.

Results
Positive staining was semiquantitatively assessed as + (from a few to one third of tumour cells positive), ++ (around half of cells positive), and +++ (from two thirds to all cells positive). The results are shown in the table. These were then averaged to arrive at an overall score.
Endothelial markers in malignant vascular tumours

<table>
<thead>
<tr>
<th>QB-END/10</th>
<th>VWF</th>
<th>UEA-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiosarcoma (AS)</td>
<td>3+</td>
<td>xxxxx</td>
</tr>
<tr>
<td>2+</td>
<td>xxx</td>
<td>xxxxx</td>
</tr>
<tr>
<td>1+</td>
<td>xx</td>
<td>xxx</td>
</tr>
<tr>
<td>0+</td>
<td>xx</td>
<td>xxxxx</td>
</tr>
<tr>
<td>Malignant haemangioendothelioma (MEH)</td>
<td>3+</td>
<td>xxx</td>
</tr>
<tr>
<td>2+</td>
<td>x</td>
<td>xxx</td>
</tr>
<tr>
<td>1+</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>0+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Number of cases tested: AS (21); MEH (7)*
AS (12); MEH (5)*
AS (19); MEH (7)*

QB-END/10 stained crisply and uniformly 14 of 21 cases of angiosarcoma and six of seven cases of malignant haemangioendothelioma, with overall scores of 2-38 and 2-85, respectively. Four cases of angiosarcoma stained poorly; this seemed to be associated with lack of fixation and post mortem autolysis. In well fixed and preserved tumours, cells stained well in “classic” areas (tumour cells covering liver cell plates in a “tectorial” manner, as well as in less typical arrangements—solid masses or “cysts” lined by ‘papillae’ (fig 1). All cases of malignant haemangioendothelioma stained well throughout (overall score 2-85) as strands or tube-like structures infiltrating the liver sinusoids (fig 2A), or as tongue-like projections within vessels (fig 2B). Intracytoplasmic lumina in small groups of tumour cells were also readily shown (Fig 2C).

VWF stained angiosarcoma moderately, with an overall score of 1-83; only two cases reacted well and one not at all. Staining was generally patchy and granular and was best seen in solid areas (fig 3). Malignant haemangioendotheliomas reacted somewhat better, with a score of 2-0; staining was again patchy.

UEA-1 performed as well as VWF in angiosarcomas with an average score of 1-89, and very well in malignant haemangioendotheliomas with a score of 2-57. Staining was crisp in all histological patterns of these two tumours. In 16 of 26 cases tested, however, bile duct epithelium or blood cells also stained strongly (fig 4).

**Discussion**

Malignant vascular tumours of the liver are rare, but they are the commonest sarcomas at this site and they have attracted much interest recently for two main reasons. One concerns aetiology. The main known aetiological agent of “classic” angiosarcoma is thorium dioxide (Thorotrast), a radiological contrast medium, that has been in use since the late 1920s: it is radioactive and emits alpha particles over the lifetime of those exposed to it. The peak incidence may have been passed but new cases continue to appear. The number of people at risk is unknown but it was estimated to be between 50,000 and 100,000 not long ago. Occupation exposure to vinyl chloride monomer is next in importance. The discovery of this hazard in the early 1970s led to the establishment of survey schemes and registrars in the United States, Germany, Great Britain and more recently, in Japan. Other agents, like arsenic, copper in vinner’s sprays, and rarely, drugs, are of much lesser importance. Angiosarcoma of the liver is therefore one of the most important examples of a malignant tumour induced by medical treatment and by industrial exposure to a known agent.

The second reason for continuing interest is difficulty in diagnosis: only one third of the cases submitted to the Angiosarcoma Panel of the Health and Safety Executive were confirmed. The same applies even more to malignant haemangioendothelioma. This tumour produces such variability in histological appearance that almost no two cases are exactly alike and new features of it continue to be described. Recognition is important as amenability to treatment is greater and prognosis is better than in the case for either angiosarcoma or other malignant tumours of the liver.

Immunocytochemistry, using antibodies raised against antigens associated with endothelial cells, is the mainstay of diagnosis in difficult cases, given the variability of histological appearances by routine, empirical methods and the need for fresh tissue for electron microscopy. Von Willebrand factor is the most commonly looked for antigen but results have been variable or poor due to weak and patchy positive reaction. Most studies concluded that it was a reasonably specific but insensitive marker. The use of UEA-1 has been confirmed in this study. Lectin cytochemistry, using UEA-1 as a marker, is much more sensitive but also less specific, and cross...
reaction with epithelia has been recorded by most authors. UEA-1 binds specifically to an oligosaccharide component of the ABO blood group, antigen H, found in red blood cells and secretory epithelia of group 0 subjects. This cross reaction was found in 16 of 26 cases in this study and, given the fact that malignant haemangioendothelioma mimicks an adenocarcinoma in appearance, it greatly diminishes its usefulness as an endothelial marker. Indeed, before the entity was recognised examples were regarded as "sclerosing cholangio-carcinomas".

QB-END/10 avoids most of the difficulties encountered with VWF and UEA-1 and is both specific and sensitive. All histological patterns of angiosarcoma and malignant haemangioendothelioma have been shown to stain clearly and well. For the time being and until more experience has been gained, however, it would be wise to use QB-END/10 in conjunction with VWF and UEA-1, but, in this study at least, QB-END/10 has proved superior to both.

We are grateful to Drs S Watts and H Molgaard for advice on the nature of CD34 and the antibodies raised against it, and we thank Mr K Miller and Miss R Baines for technical support and Mrs G Marshall for secretarial assistance.

QB-END/10 is now marketed by Serotec, 22 Bankside, Station Approach, Kidlington, Oxford OX5 1JE UK.

Endothelial markers in malignant vascular tumours of the liver: superiority of QB-END/10 over von Willebrand factor and Ulex europaeus agglutinin 1.

P P Anthony and P Ramani

doi: 10.1136/jcp.44.1.29

Updated information and services can be found at:
http://jcp.bmj.com/content/44/1/29

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/